Apixaban in Patients with Atrial Fibrillation | NEJM
Original Article from The New England Journal of Medicine — Apixaban in Patients with Atrial Fibrillation
Related Articles
Disease Progression in Exercise-Induced Arrhythmogenic Cardiomyopathy Compared With Arrhythmogenic Right Ventricular Cardiomyopathy:
AbstractBackgroundArrhythmogenic right ventricular cardiomyopathy (ARVC) is an inheritable heart disease, whereas exercise-induced arrhythmogenic cardiomyopathy (EiAC) is a proposed acquired simila…
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
AbstractBackgroundLong-term safety and efficacy data for aficamten in symptomatic obstructive hypertrophic cardiomyopathy are needed.ObjectivesThis study aims to evaluate 48-week experience from th…
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
AbstractBackgroundLong-term safety and efficacy data for aficamten in symptomatic obstructive hypertrophic cardiomyopathy are needed.ObjectivesThis study aims to evaluate 48-week experience from th…
Lab Assistant in Portland, Oregon | Careers at Portland, OR (Waterfront)
1. Always promotes the mission of the Knight Cardiovascular Institute through our Professional Standards of timely Customer Service, Reliability, Productivity, Professionalism, Accuracy, Timeliness, Integrity, and…
Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography:
AbstractBackgroundEarly detection of transthyretin cardiac amyloidosis (ATTR-CA) is vital, because currently available therapies are most effective early in the disease course. Although Perugini gr…
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | NEJM
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial…
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy – PubMed
In a contemporary cohort of tafamidis-treated patients with ATTR-CM, 39% of patients died over a median of 43 months. Further work is needed to improve…
Expert Insights Into Amyloidosis: Do You Need a Heart Biopsy to Diagnose Cardiac Amyloidosis?
Dr. Ahmad Masri, Director of the Cardiac Amyloidosis Program at Oregon Health & Science University (OHSU), reminds us about the traditional approach to diagn…
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy:
AbstractBackgroundVutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIO…
Reducing Granules Without Splicing Restoration Alleviates RBM20 Cardiomyopathy | Circulation Research
BACKGROUND: RBM20 (RNA binding motif protein 20) cardiomyopathy is a severe form of dilated cardiomyopathy (DCM). Genetic variants in the nuclear localization signal of Rbm20…